Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ariella who wrote (1449)	10/20/1998 4:54:00 PM
From: Rick Strange	Read Replies (2) of 1491

Anyone have any idea why 2/3rds of the patients in the 3rd cohort of the current HU-211 Phase II trial are getting dexanabinol (200mg.) vs a 50% split between drug and control in the other two cohorts. Does this indicate that the higher dosage has shown greater efficacy in the completed two cohorts of the trial?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next